Skip to search formSkip to main contentSkip to account menu

MLN 944

Known as: MLN-944, MLN944 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Phenazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Structures and dynamics of DNA complexes of the desmethyl analog of the cytotoxin MLN944: Insights into activity when a methyl isn't futile
Structure activity relationships for tricyclic‐carboxamide topoisomerase II poisons indicate that cytotoxicity is enhanced by the… 
2014
2014
The solution structure of bis(phenazine‐1‐carboxamide)‐DNA complexes: MLN 944 binding corrected and extended
MLN 944 is a bisintercalating DNA‐binding antitumor agent known to be a template inhibitor of transcription. Previous 1H NMR… 
2005
2005
The antiproliferative agent MLN944 preferentially inhibits transcription
MLN944 is a novel compound currently being codeveloped by Millennium Pharmaceuticals and Xenova Ltd. as a cancer therapeutic and… 
2005
2005
Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma
XR5944 (MLN944) is a novel bis-phenazine currently in phase I clinical trials that has demonstrated potent cytotoxic activity… 
2004
2004
Initial phase I study of XR5944, a novel DNA and RNA targeting agent.
2100 Background: XR5994 (MLN944) is a novel DNA/RNA targeting agent with a mechanism of action distinct from that of currently… 
2004
2004
Erratum: Novel DNA Bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug (The Journal of Biological Chemistry (2004) 279 (46096-46103))
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)